US FDA Backs EPCIS, Refines Advice As November 2023 DSCSA Deadline Approaches
Executive Summary
Agency recommends the GS1 standard that stakeholders have been focusing on for working together to remove counterfeits from the US pharmaceutical distribution chain; adds its latest thinking on roles of additional types of trading partners.
You may also be interested in...
RFID Tags Found To Improve Drug Supply Chain Tracking In Recent DSCSA Pilot
A pilot that used RFID tags with 2D barcodes was touted as more effective than using 2D barcodes alone in tracking drugs through the supply chain.
DSCSA Pilot Used Blockchain To Trace Drug Through 'Last Mile' of Supply Chain
A blockchain application for mobile devices was successfully piloted to conduct real-time tracking of a high-cost drug through the “last mile” of the supply chain to the point of dispensing. Such a tool can be useful for manufacturers in tracing their products through the supply chain and complying with a forthcoming mandate of the US FDA Drug Supply Chain Security Act (DSCSA).
FDA Drafts Guidance To Dispel Confusion About DSCSA Trading Partners
FDA draft guidance clarifies the roles of the different supply chain partners under the Drug Supply Chain Security Act. While much attention has focused on the serialization challenges in implementing DSCSA, less attention has been paid to which trading partners are authorized to transfer products.